Paraneoplastic Syndromes: Clinical Trials

90 trials for Paraneoplastic Syndromes, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

34 completed, 24 recruiting, 12 terminated, 9 active not recruiting. 90 Phase 2, 14 Phase 3, 12 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 290Completed 34, Recruiting 24, Terminated 12, Active not recruiting 9, Not yet recruiting 4, Unknown 3, Withdrawn 3, Enrolling by invitation 1
Phase 314Recruiting 6, Unknown 2, Active not recruiting 1, Completed 1, Enrolling by invitation 1, Not yet recruiting 1, Terminated 1, Withdrawn 1
Phase 112Recruiting 5, Completed 4, Active not recruiting 2, Not yet recruiting 1

Follow Paraneoplastic Syndromes: new trials by email Literature Review of Paraneoplastic Syndromes trials Research Report on Paraneoplastic Syndromes

Trials (filtered) newest first · largest first

All 90 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old
Felzartamab, Placebo - Generalized Myasthenia Gravis
Phase 2Not yet recruitingBiogen752026-11-192026-11-16
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Ublituximab, Placebo - Myasthenia Gravis
Phase 2RecruitingTG Therapeutics, Inc.1202026-11-012026-10-29
Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
Metyrapone 250 mg Oral Tablets, Placebo - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Phase 2RecruitingMayo Clinic902026-10-192026-11-17
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
SHR-2173 injection, Placebo - Generalized Myasthenia Gravis
Phase 2RecruitingGuangdong Hengrui Pharmaceutical Co., Ltd602026-08-282026-10-22
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Inebilizumab - Generalized Myasthenia Gravis
Phase 2RecruitingAmgen152026-07-212026-10-23
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS - AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG)
Phase 2Recruitingargenx402026-07-102026-11-16
Efgartigimod in Anti-NMDA Receptor Encephalitis.
Efgartigimod Alfa - Encephalitis Autoimmune
Phase 2RecruitingBeijing Tongren Hospital202026-06-252026-09-16
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Povetacicept, Placebo - Myasthenia Gravis, Generalized
Phase 2Active not recruitingVertex Pharmaceuticals Incorporated342026-05-132026-10-29
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Aritinercept, Placebo - Myasthenia Gravis, Generalized
Phase 1 / Phase 2RecruitingAurinia Pharmaceuticals Inc.812026-04-222026-08-03
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
IM-101 Part A, Placebo Part A, IM-101 Part B - Myasthenia Gravis
Phase 1 / Phase 2RecruitingImmunAbs Inc.962026-02-052026-02-11
Ripertamab for the Treatment of Myasthenia Gravis
ripertamab - Myasthenia Gravis (MG)
Phase 1 / Phase 2Not yet recruitingZhongming Qiu202026-02-012026-01-28
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
Osilodrostat 1 MG - Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS)
Phase 2RecruitingMayo Clinic152026-01-142026-02-11
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Efgartigimod IV, Empasiprubart IV - AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis
Phase 2Recruitingargenx702025-12-192026-09-24
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
clofutriben, Placebo - Type 2 Diabetes, Cortisol Excess
Phase 2RecruitingSparrow Pharmaceuticals15002025-11-292026-10-06
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
YTB323 - Generalized Myasthenia Gravis
Phase 1 / Phase 2Active not recruitingNovartis Pharmaceuticals152025-04-222026-09-04
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
BAFF-R CART - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder
Phase 1 / Phase 2RecruitingTianjin Medical University General Hospital272025-04-102026-10-16
Blinatumomab for Treatment of Refractory Myasthenia Gravis
Blinatumomab - Myasthenia Gravis
Phase 2 / Phase 3Not yet recruitingDa, Yuwei, M.D.22025-04-012025-03-25
Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy
Immunoglobulins IV (CLAYRIG), Cyclophosphamide IV, Methylprednisolone IV - Paraneoplastic Sensory Neuronopathy
Phase 2RecruitingAssistance Publique - Hôpitaux de Paris212025-01-102025-02-17
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
CABA-201 - Generalized Myasthenia Gravis (gMG)
Phase 1 / Phase 2RecruitingCabaletta Bio242024-12-172026-10-19
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
Taitacept - Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Phase 2RecruitingBeijing Tongren Hospital102024-12-012024-11-20

Showing 20 of 90. Sign in to see all of them.

Narrower conditions

Myasthenia Gravis (58)  ·  ACTH Syndrome, Ectopic (12)  ·  Cushing Syndrome (10)  ·  Zollinger-Ellison Syndrome (6)  ·  Myelitis, Transverse (5)  ·  Autoimmune Diseases (4)  ·  Neuromyelitis Optica (4)  ·  Pituitary ACTH Hypersecretion (4)  ·  Adrenal Cortex Neoplasms (3)  ·  Adrenal Hyperplasia, Congenital (3)  ·  Anti-N-Methyl-D-Aspartate Receptor Encephalitis (3)  ·  Autoimmune Diseases of the Nervous System (3)  ·  Diabetes Mellitus, Type 2 (3)  ·  Gastrinoma (3)  ·  Opsoclonus-Myoclonus Syndrome (3)

Broader conditions

Neoplasms (90)  ·  Neoplasms by Site (80)  ·  Nervous System Diseases (76)  ·  Nervous System Neoplasms (72)  ·  Neurodegenerative Diseases (71)  ·  Paraneoplastic Syndromes, Nervous System (71)  ·  Immune System Diseases (68)  ·  Autoimmune Diseases of the Nervous System (65)  ·  Autoimmune Diseases (64)  ·  Neuromuscular Diseases (60)  ·  Neuromuscular Junction Diseases (59)  ·  Paraneoplastic Endocrine Syndromes (18)  ·  Central Nervous System Diseases (17)  ·  Endocrine System Diseases (16)

Interventions

Rituximab (6)  ·  efgartigimod alfa (3)  ·  Hizentra (2)  ·  Immunoglobulins, Intravenous (2)  ·  Metyrapone (2)  ·  Osilodrostat (2)  ·  eculizumab (2)  ·  gamma-Globulins (2)  ·  pasireotide (2)  ·  relacorilant (2)  ·  rozanolixizumab (2)  ·  zilucoplan (2)  ·  4-Aminopyridine (1)  ·  ASP3662 (1)  ·  Albuterol (1)

Sponsors

argenx (6)  ·  Alexion Pharmaceuticals, Inc. (4)  ·  Novartis Pharmaceuticals (4)  ·  Assistance Publique - Hôpitaux de Paris (3)  ·  Mayo Clinic (3)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3)  ·  Tang-Du Hospital (3)  ·  Beijing Tongren Hospital (2)  ·  Corcept Therapeutics (2)  ·  CuraVac (2)  ·  Grifols Therapeutics LLC (2)  ·  Momenta Pharmaceuticals, Inc. (2)  ·  Sparrow Pharmaceuticals (2)  ·  UCB Biopharma SRL (2)  ·  American University of Beirut Medical Center (1)

Countries

United States (62)  ·  Canada (24)  ·  Italy (20)  ·  Poland (20)  ·  Germany (17)  ·  Spain (17)  ·  Belgium (15)  ·  France (14)  ·  United Kingdom (13)  ·  Netherlands (11)  ·  China (9)  ·  Japan (7)  ·  Denmark (6)  ·  Serbia (6)  ·  Czechia (5)

Top investigators

Irina Bancos, MD (2)  ·  Rudy Mercelis, MD, PhD (2)  ·  Andreas G Moraitis, MD (1)  ·  Andreas Meisel, Prof. Dr. (1)  ·  Andrew Wolff, MD, FACC (1)  ·  Antonio Guglietta, MD (1)  ·  Benjamin Greenberg, MD (1)  ·  Charles M. Epstein, M.D. (1)  ·  Chongbo Zhao (1)  ·  Dimitri Psimaras, MD (1)  ·  Falk Hiepe, Prof. Dr. (1)

Results publications

PMID 35350948, PMID 19838774, PMID 20606544, PMID 21211990, PMID 23512355, PMID 25956795, PMID 26539981, PMID 28801338, PMID 30130439, PMID 32065623, PMID 32098874, PMID 33219142, PMID 34335465, PMID 34857535, PMID 35058882, PMID 35412216, PMID 36270895, PMID 37166675, PMID 37259693, PMID 37353270, PMID 37353278, PMID 38099334, PMID 38165333, PMID 39720510, PMID 40320172, PMID 40913424, PMID 41224659, PMID 41514038, PMID 41514039, PMID 42043793

NIH funding

2025 (6), 2023 (4), 2016 (2), 2018 (2), 2019 (2), 1RC3NS070670-01 (1), 2008 (1), 2015 (1), 2017 (1), N01CM62202 (1), P30CA016672 (1), U01CA062490 (1), U01NS077179 (1), U01NS077352 (1), U01NS084495 (1)